Compare · MMM vs NYXH
MMM vs NYXH
Side-by-side comparison of 3M Company (MMM) and Nyxoah SA (NYXH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MMM and NYXH operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MMM is the larger of the two at $85.26B, about 716.0x NYXH ($119.1M).
- MMM has been more active in the news (8 items in the past 4 weeks vs 3 for NYXH).
- MMM has more recent analyst coverage (25 ratings vs 9 for NYXH).
- Company
- 3M Company
- Nyxoah SA
- Price
- -
- -
- Market cap
- $85.26B
- $119.1M
- 1M return
- -0.03%
- -
- 1Y return
- +6.41%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 8
- 3
- Recent ratings
- 25
- 9
3M Company
3M Company develops, manufactures, and markets various products worldwide. It operates through four business segments: Safety and Industrial, Transportation and Electronics, Health Care, and Consumer. The Safety and Industrial segment offers personal safety products, industrial adhesives and tapes, abrasives, closure and masking systems, electrical markets, automotive aftermarket, and roofing granules to industrial, electrical, and safety markets. The Transportation and Electronics provides electronics, such as display materials and systems, electronic materials solutions; automotive and aerospace, and commercial solutions; advanced materials; and transportation safety products to transportation and electronic original equipment manufacturer customers. The Health Care segment offers medical and surgical supplies, skin health and infection prevention products, oral care, separation and purification sciences, health information systems, drug delivery systems, and food safety products to healthcare industry. The Consumer segment provides home improvement, home care, and consumer health care products, as well as stationery and office supplies to various consumers. This segment is also involved in the retail auto care business. It offers its products through various e-commerce and traditional wholesalers, retailers, jobbers, distributors, and dealers, as well as directly to users. 3M Company has a strategic collaboration with Merry Maids in residential cleaning sector; and collaborations with The Infectious Disease Research Institute and Duke Human Vaccine Institute to create a vaccine candidate with potential to provide protection against multiple variants of SARS-CoV-2. The company was founded in 1902 and is headquartered in St. Paul, Minnesota.
Nyxoah SA
Nyxoah S.A., a health-technology company, focuses on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. It offers Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treast moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is based in Mont-Saint-Guibert, Belgium.
Latest MMM
- Amendment: SEC Form SCHEDULE 13G/A filed by 3M Company
- 13-Year-old Raji Doshi named America's Top Young Scientist for inventing an algae-aragonite alkalinity system to reduce CO2-driven ocean acidification
- SEC Form 4 filed by 3M Company
- SEC Form 4 filed by 3M Company
- SEC Form 4 filed by 3M Company
- SEC Form 3 filed by 3M Company
- 3M Announces Upcoming Investor Event
- EVP & Chief Financial Officer Maheshwari Anurag exercised 10,944 shares at a strike of $163.02 and covered exercise/tax liability with 4,991 shares, increasing direct ownership by 93% to 12,365 units (SEC Form 4)
- Wells Fargo initiated coverage on 3M with a new price target
- 3M upgraded by Bernstein with a new price target
Latest NYXH
- Full 12-Month Data from the ACCCESS U.S. Pivotal Study in Complete Concentric Collapse Patients Presented at ISSS 2026
- SEC Form 6-K filed by Nyxoah SA
- Nyxoah Appoints Liam Kelly as Chief Executive Officer
- SEC Form 6-K filed by Nyxoah SA
- CVRx Appoints John Landry as Chief Financial Officer
- Nyxoah Announces Chief Financial Officer Transition
- Nyxoah Announces First Patient Implanted in BREATHE, the U.S. Post-Approval Study of the Genio® System
- Nyxoah Announces ACCCESS U.S. Pivotal Study Meets Primary Safety and Efficacy Endpoints in Complete Concentric Collapse Patients
- Information on the total number of voting rights and shares
- Amendment: SEC Form SCHEDULE 13G/A filed by Nyxoah SA